comparemela.com

Latest Breaking News On - Cantargia - Page 9 : comparemela.com

Cantargia AB: Cantargia reports positive preclinical efficacy data for CAN10 demonstrating anti-fibrotic and anti-inflammatory effects in systemic sclerosis

STOCKHOLM, March 1, 2022 /PRNewswire/ Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today announced new preclinical data on its anti-inflammatory IL1RAP-binding antibody CAN10 showing

Prnewswire cantargiaSystemic sclerosis world congressFriedrich alexander university erlangenSsc congress pr engNasdaq stockholmFriedrich alexander university erlangen nAccessory protein

Cantargia AB: Cantargia publishes full year report for 2021

STOCKHOLM, Feb. 24, 2022 /PRNewswire/ Cantargia AB's ("Cantargia") full year report for 2021 is now available on the company's web page www.cantargia.com/en/investors/financial-reports. Significant

United kingdomEuropean patent officeEuropean medicines agencyPancreatic cancer action network panPancreatic cancer action networkNasdaq stockholmYear report

Cantargia AB: Invitation to presentation of Cantargia s report for the fourth quarter of 2021 on February 24 at 3 00 p m CET

STOCKHOLM, Feb. 8, 2022 /PRNewswire/ Cantargia AB will publish the company's report for the fourth quarter for 2021 on Thursday, February 24, 2022, at 08.30 a.m. CET. In conjunction

United kingdomKostenloser wertpapierhandelNasdaq stockholm

Cantargia AB: Cantargia reports treatment of first non-squamous non-small cell lung cancer patient in new arm of CANFOUR study

STOCKHOLM, Feb. 4, 2022 /PRNewswire/ Cantargia AB today reported that the first patient in the new non-squamous non-small cell lung cancer (NSCLC) therapy arm of the CANFOUR study has received

Nasdaq stockholm

Cantargia AB: Cantargia reports positive safety data from CIRIFOUR clinical study on nadunolimab and pembrolizumab combination

STOCKHOLM, Feb. 3, 2022 /PRNewswire/ Cantargia AB today reported an interim update on the first part of the phase Ib clinical study CIRIFOUR. Fifteen cancer patients no longer responding

Nasdaq stockholm

vimarsana © 2020. All Rights Reserved.